Definium Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
DFTX$34.64-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2025 | 2024 |
| Operating expenses: | ||
| Research and development | $117,665 | $65,297 |
| General and administrative | 48,644 | 38,619 |
| Total operating expenses | 166,309 | 103,916 |
| Loss from operations | (166,309) | (103,916) |
| Other income/(expense): | ||
| Interest income | 10,960 | 11,558 |
| Interest expense | (5,482) | (2,283) |
| Foreign exchange loss, net | (131) | (638) |
| Change in fair value of 2022 USD Financing Warrants | (22,831) | (15,941) |
| Gain on extinguishment of contribution payable | — | 2,541 |
| Total other expense, net | (17,484) | (4,763) |
| Net loss | (183,793) | (108,679) |
| Other comprehensive loss | ||
| Unrealized gain on investments | 330 | — |
| Gain/(loss) on foreign currency translation | (64) | 476 |
| Comprehensive loss | $(183,527) | $(108,203) |
| Net loss per common share, basic and diluted | $(2.06) | $(1.54) |
| Weighted-average common shares, basic and diluted | 89,327,608 | 70,461,067 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.